Thus, immune status is important in explaining variation in DFS and OS across multiple cohorts even when patient age, tumor stage, BRCA1/2 somatic mutational status, tumor cytoreduction, and COL2A1 expression is known. Here, COL2A1 is linked to neoplasm.